The mechanism of procyanidin B1 in the treatment of nonalcoholic fatty liver disease based on network pharmacology and molecular docking

Abstract

Non-alcoholic fatty liver disease (NAFLD), a chronic liver disorder closely associated with metabolic dysfunction, has become a significant global health challenge. In recent years, procyanidin B1 (PB1) has demonstrated potential advantages in the prevention and personalized treatment of NAFLD through multi-target and multi-pathway intervention strategies, exerting comprehensive regulatory and synergistic effects. However, its precise therapeutic mechanisms remain unclear. This study employs network pharmacology to identify key targets and potential pathways involved in the treatment of NAFLD with PB1. Additionally, molecular docking analysis is conducted to validate the reliability of these targets. The findings provide a theoretical foundation for the development of PB1 as a potential therapeutic agent for NAFLD, offering insights for future experimental and clinical research.

Keywords

Procyanidin B1 / non-alcoholic fatty liver disease / network pharmacology / molecular docking